Literature DB >> 26898804

Manifestations and characteristics of congenital adrenal hyperplasia-associated encephalopathy.

Yuichi Abe1, Tetsuro Sakai2, Akihisa Okumura3, Shinjiro Akaboshi4, Mitsumasa Fukuda5, Kazuhiro Haginoya6, Shin-Ichiro Hamano7, Kouichi Hirano8, Kenjiro Kikuchi9, Masaya Kubota10, Sooyoung Lee11, Yoshihiro Maegaki12, Masafumi Sanefuji13, Sachiko Shimozato14, Motomasa Suzuki15, Yasuhiro Suzuki16, Mitsugi Takahashi17, Kenji Watanabe18, Masashi Mizuguchi19, Hideo Yamanouchi2.   

Abstract

BACKGROUND: This study aimed to clarify the characteristics of acute encephalopathic episodes in patients with congenital adrenal hyperplasia (CAH), which we termed "CAH-associated encephalopathy (CAHE)."
METHODS: This retrospective study was conducted using a questionnaire as a nationwide survey of patients with CAH with acute encephalopathy and related episodes.
RESULTS: Fifteen patients were recruited on the bases of clinical data that supported a diagnosis of CAHE. Fourteen patients displayed seizures at onset, and 12 patients exhibited refractory seizures. Deep coma lasting >24h was noted in 12 patients. Neuroimaging studies revealed some heterogeneous features. Diffuse or focal edematous lesions in the cerebrum, which produce high signal intensity on diffusion-weighted magnetic resonance imaging or low density on computer tomography, were found in the acute period in all 15 patients. In the chronic period, 14 patients survived, 11 of whom had some degree of neurological sequelae. Moreover, various degrees of cerebral shrinkage were observed in 11 of 14 surviving patients. Surprisingly, there were no abnormal neuroimaging findings in the basal ganglia, brainstem, and cerebellum in any patient.
CONCLUSION: Our results indicated that patients with CAH have a risk of developing CAHE, and thus, they should be followed closely because not only status epilepticus or deep coma but also minor symptoms, such as fever and nausea, may lead to CAHE. Because CAHE may feature some heterogeneous encephalopathic episodes, further validation is needed to clarify its etiology.
Copyright © 2016 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute encephalopathy; Acute encephalopathy with biphasic seizures and late reduced diffusion; Acute encephalopathy with febrile convulsive status epilepticus; Clinically mild encephalopathy/encephalitis with reversible splenial lesion type 2; Congenital adrenal hyperplasia; Congenital adrenal hyperplasia-associated encephalopathy; Hemiconvulsion-hemiplegia-epilepsy syndrome

Mesh:

Year:  2016        PMID: 26898804     DOI: 10.1016/j.braindev.2016.01.007

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  5 in total

1.  Ambiguous Genitalia and Lissencephaly in A 46,XY Neonate with a Novel Variant of Aristaless Gene.

Authors:  M Basa; R Vukovic; A Sarajlija; T Milenkovic; M Djordjevic; B Vucetic; J Martic
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

2.  Congenital Adrenal Hyperplasia and Brain Health: A Systematic Review of Structural, Functional, and Diffusion Magnetic Resonance Imaging (MRI) Investigations.

Authors:  Noor Khalifeh; Adam Omary; Devyn L Cotter; Mimi S Kim; Mitchell E Geffner; Megan M Herting
Journal:  J Child Neurol       Date:  2022-06-23       Impact factor: 2.363

3.  Longitudinal Assessment of Illnesses, Stress Dosing, and Illness Sequelae in Patients With Congenital Adrenal Hyperplasia.

Authors:  Diala El-Maouche; Courtney J Hargreaves; Ninet Sinaii; Ashwini Mallappa; Padmasree Veeraraghavan; Deborah P Merke
Journal:  J Clin Endocrinol Metab       Date:  2018-06-01       Impact factor: 5.958

Review 4.  Management challenges and therapeutic advances in congenital adrenal hyperplasia.

Authors:  Ashwini Mallappa; Deborah P Merke
Journal:  Nat Rev Endocrinol       Date:  2022-04-11       Impact factor: 47.564

Review 5.  A Comprehensive Review of Pediatric Acute Encephalopathy.

Authors:  George Imataka; Shigeko Kuwashima; Shigemi Yoshihara
Journal:  J Clin Med       Date:  2022-10-07       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.